{"entity":{"id":"nct07286331","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","aka":[],"tldr":"A phase 3 trial of Doxorubicin in endometrial cancer, run by GlaxoSmithKline, now recruiting.","summary":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) is a phase 3 interventional study registered as NCT07286331 by GlaxoSmithKline, with 600 participants planned, started 2026-06-04 and due to reach its primary completion in 2028-02-29. Interventions recorded: Mocertatug rezetecan, Paclitaxel and Doxorubicin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07286331","url":"https://clinicaltrials.gov/study/NCT07286331"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["doxorubicin"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07286331","phase":"3","setting":"A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy","sponsor":"GlaxoSmithKline","enrolled":600,"outcomes":[]},"route":"/trials/nct07286331/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}